Allergan looks to spend on new programs

|About: Allergan plc (AGN)|By:, SA News Editor

"We can afford to pay more than anyone else," FierceBiotech quotes Allergan (AGN +0.5%) CEO David Pyott as saying, in reference to the company's desire to add researchers and make acquisitions in 2014.

AGN "is in a position to spend up to $10B in cash for new deals," John Carroll notes, citing Pyott.

As for 18-month delays in the Darpin and bimatoprost programs, Pyott doesn't understand the concern: "Is it that big a deal? I don't get it."